Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJPS (2) Autor Monteiro,Gisele (2) Pimenta,Marcela Valente (1) Sousa,Graziele Fonseca de (1) Wlodarczyk,Samarina Rodrigues (1) Palavra-chave Antitumors/platinum-based (1) Biological drugs (1) Biopharmaceutical (1) Biosimilar (1) Brazilian biopharmaceutical market (1) Carboplatin/mechanisms of resistance (1) Cisplatin/mechanisms of resistance (1) Drugs/resistance (1) Molecular targets (1) Mais... Tipo do documento Info:eu-repo/semantics/article (2) Ano 2019 (1) 2014 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última The production of biopharmaceuticals in Brazil: current issues BJPS Pimenta,Marcela Valente; Monteiro,Gisele. Biopharmaceuticals are gaining a growing share of the pharmaceuticals market. In recent years, the Brazilian Health Surveillance Agency (ANVISA) has approved the registration of biological drugs with domestic production. Although Brazil is in the early stages of biopharmaceutical production, governmental incentives and the investment in private companies in the technological domain in this country have created expectations of an increase in the capacity of biopharmaceutical production. Private initiatives, once rare, have now started to blossom in this field, such as collagenase from Cristalia and filgrastim from Eurofarm. The expiry of the patents for certain biopharmaceuticals (e.g. infliximab, filgrastim and rituximab) has generated the possibility of... Tipo: Info:eu-repo/semantics/article Palavras-chave: Biopharmaceutical; Biosimilar; Biological drugs; Brazilian biopharmaceutical market. Ano: 2019 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502019000100599 Carboplatin: molecular mechanisms of action associated with chemoresistance BJPS Sousa,Graziele Fonseca de; Wlodarczyk,Samarina Rodrigues; Monteiro,Gisele. Carboplatin is a derivative of cisplatin; it has a similar mechanism of action, but differs in terms of structure and toxicity. It was approved by the FDA in the 1980s and since then it has been widely used in the treatment of several tumor types. This agent is characterized by its ability to generate lesions in DNA through the formation of adducts with platinum, thereby inhibiting replication and transcription and leading to cell death. However, its use can lead to serious inconvenience arising from the development of resistance that some patients acquire during treatment, limiting the scope of its full potential. Currently, the biochemical mechanisms related to resistance are not precisely known. Therefore, knowledge of pathways associated with... Tipo: Info:eu-repo/semantics/article Palavras-chave: Carboplatin/mechanisms of resistance; Cisplatin/mechanisms of resistance; Drugs/resistance; Molecular targets; Antitumors/platinum-based. Ano: 2014 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502014000400693 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco